Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 2, 2013, Pages 110-116

  Maher, Kristin N ^a   Tan, Marcus ^a   Tossell, Julia W ^a   Weisinger, Brian ^a   Gochman, Peter ^a   Miller, Rachel ^a   Greenstein, Deanna ^a   Overman, Gerald P ^a   Rapoport, Judith L ^a   Gogtay, Nitin ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LITHIUM CARBONATE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; ETHNICITY; FEMALE; GENDER; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; NEUTROPHIL COUNT; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; SCHOOL CHILD;

ADOLESCENT; AFRICAN AMERICANS; AGE FACTORS; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LEUKOCYTE COUNT; MALE; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UNITED STATES;

EID: 84875447775     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0136     Document Type: Article

References (41)

1. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329:162-167, 1993.
2. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P: Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 56:241-248, 1977.
3. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D: Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483-488, 1996.
4. Bender S, Linka T, Wolstein J, Gehendges S, Paulus HJ, Schall U, Gastpar M: Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol 7:59-63, 2004.
5. Benedetti F, Cavallaro R, Smeraldi E: Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 354:567, 1999.
6. Blackman G: Benign ethnic neutropenia and clozapine monitoring. J Am Acad Child Adolesc Psychiatry 47:967-968, 2008.
7. Caramihai E, Karayalcin G, Aballi AJ, Lanzkowsky P: Leukocyte count differences in healthy white and black children 1 to 5 years of age. J Pediatr 86:252-254, 1975.
8. Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF: Clozapine treatment in Australia: A review of haematological monitoring. Med J Aust 168:495-497, 1998.
9. Cosar B, Taner ME, Eser HY, Altinoz AE, Tarhan R: Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients. J Clin Psychopharmacol 31:169-173;2011.
10. Crilly J: The history of clozapine and its emergence in the US market: A review and analysis. Hist Psychiatry 18:39-60, 2007.
11. Esposito D, Rouillon F, Limosin F: Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 60:759-764, 2005.
12. Flanagan RJ, Dunk L: Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 23:27-41, 2008.
13. Flynn SW, Altman S, Macewan GW, Black LL, Greenidge LL, Honer WG: Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J Clin Psychopharmacol 17:494-495, 1997.
14. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C: Efficacy and safety of secondgeneration antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621-645, 2010.
15. Frazier JA, Cohen LG, Jacobsen L, Grothe D, Flood J, Baldessarini RJ, Piscitelli S, Kim GS, Rapoport JL: Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 23:87-91, 2003.
16. Gerbino-Rosen G, Roofeh D, Tompkins D, Feryo D, Nusser L, Kranzler H, Napolitano B, Frederickson A, Henderson I, Rhinewine J, Kumra S: Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 44:1024-1031, 2005.
17. Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ Jr., Meltzer H: Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 338:262-263, 1991.
18. Gerson SL: Clozapine-deciphering the risks. N Engl J Med 329:204-205, 1993.
19. Gogtay N, Rapoport J: Clozapine use in children and adolescents. Expert Opin Pharmacother 9:459-465, 2008.
20. Hippius H: The history of clozapine. Psychopharmacology (Berl), 99 Suppl:S3-5, 1989.
21. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP: Prevalence of neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. Ann Intern Med 146:486-492, 2007.
22. Kang BJ, Cho MJ, OH JT, Lee Y, Chae BJ, KO J: Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: When is it safe to discontinue CPMS? Hum Psychopharmacol 21:387-391, 2006.
23. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR: Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 33:1221-1224, 2007.
24. Kranzler H, Roofeh D, Gerbino-Rosen G, Dombrowski C, Mcmeniman M, Dethomas C, Frederickson A, Nusser L, Bienstock MD, Fisch GS, Kumra S: Clozapine: Its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44:55-63, 2005.
25. Kumra S, Frazier JA, Jacobsen LK, Mckenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090-1097, 1996.
26. Kumra S, Oberstar JV, Sikich L, Findling Rl,Mcclellan JM, Vinogradov S, Charles Schulz S: Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60-71, 2008.
27. Manu P, Sarpal D, Muir O, Kane JM, Correll CU: When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134:180-186, 2012.
28. Mattai A, Fung L, Bakalar J, Overman G, Tossell J, Miller R, Rapoport J, Gogtay N: Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol 24:584-589, 2009.
29. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610, 2006.
30. McKee JR, Wall T, Owensby J: Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients. Clin Schizophr Relat Psychoses 5:26-32, 2011.
31. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin, R: Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 175:576-580, 1999.
32. Nicolson R, Rapoport JL: Childhood-onset schizophrenia: Rare but worth studying. Biol Psychiatry 46:1418-1428, 1999.
33. Rajagopal S: Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J, 81:545-546, 2005.
34. Rana SR, Castro OL, Haddy TB: Leukocyte counts in 7,739 healthy black persons: Effects of age and sex. Ann Clin Lab Sci 15:51-54, 1985.
35. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL: Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721-730, 2006.
36. Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport Jl: Clozapine-induced neutropenia in children: Management with lithium carbonate. J Child Adolesc Psychopharmacol 13:401-404, 2003.
37. Teter CJ, Early JJ, Frachtling RJ: Olanzapine-induced neutropenia in patients with history of clozapine treatment: Two case reports from a state psychiatric institution. J Clin Psychiatry 61:872-873, 2000.
38. Valevski A, Modai I, Lahav M, Weizman A: Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 8:63-65, 1993.
39. Wahlbeck K, Cheine M, Essali MA: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2:CD000059, 2000.
40. Whiskey E, Olonfinjana O, Taylor D: The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: Case reports and database study. J Psychopharmacol 25:842-845, 2011.
41. Whiskey E, Taylor D: Restarting clozapine after neutropenia: Evaluating the possibilities and practicalities. CNS Drugs, 21:25-35, 2007.